

ASX ANNOUNCEMENT

US PATENT FOR ANTI-MIDKINE ANTIBODIES GRANTED

- Allowance of US patent for anti-midkine antibodies to prevent and treat cancer, inflammatory and autoimmune diseases
- Key member of one of Cellmid's most commercially important patent families, integral to Cellmid's CAB102 antibody cancer program
- Final granted patent in global patent family; patents already in force in Europe, Australia and Japan

SYDNEY, Monday, 29 June 2015: Cellmid Limited (ASX: CDY) The US Patent Office has issued a Notice of Allowance for Cellmid's patent application 12/312,522 entitled "Antibody recognising C-domain of midkine". The granted claims cover antibodies and antibody fragments which bind to the important functional C-domain of growth factor midkine (MK). In particular, antibodies of any kind that bind to key MK C-domain epitopes are covered.

Significantly, this patent also includes composition of matter claims for MK-specific antibodies, including Cellmid's lead humanised antibody CAB102. The granted claims cover the use of any such antibodies for prevention and treatment of cancer, autoimmune diseases, inflammatory diseases, and any disease or disorder attributed to cell migration.

In numerous published studies, the MK C-domain has been demonstrated as the key region promoting signalling and pathology attributed to MK. Blocking the C-domain therefore represents a powerful potential treatment option in many MK-related diseases as has been shown in a number of animal models.

"Having this patent granted in US for our MK antibodies across such a wide array of diseases is a tremendous commercial outcome for Cellmid", said Cellmid CEO Maria Halasz. "This patent adds to already covered territories of Europe, Japan and Australia. This family gives Cellmid strong and exclusive rights to develop MK antibodies unencumbered by competition. Moreover, Cellmid's patent coverage for its therapeutic antibodies now extends across cancer, inflammatory and autoimmune diseases, and surgical adhesion."

Cellmid holds the most significant intellectual property assets related to MK worldwide. Cellmid's patent portfolio currently includes 88 patents in 21 patent families, which cover use of MK and anti-MK agents for therapeutic purposes in a number of diseases, as well as the use of MK as a diagnostic marker in cancer and other disorders.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is a revenue stage Australian biotechnology company with a strong product pipeline. The Company generates revenue through its consumer health business and is also developing innovative novel therapies and diagnostic tests for a number of cancer inflammatory indications. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only present in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.